Lumaris
Summary
A senior scientist spending three months on a systematic literature review is three months not running experiments — and most teams accept that cost because they don't have an alternative that doesn't just return a pile of PDFs.
Lumaris generates structured intelligence reports from a defined therapeutic question, pulling across PubMed, bioRxiv, clinical trial registries, patent literature, and preprint servers — the vendor states 35M+ papers indexed, updated daily. You define the scope, an onboarding team helps frame the question, and a cited report with evidence strength ratings and identified gaps arrives within 48 hours. That workflow fits well for a pre-IND competitive scan or a target validation brief ahead of a portfolio review. It breaks down when your team needs continuous monitoring with alerts rather than discrete on-demand reports, or when the question requires proprietary internal data woven into the synthesis. There is no API, so nothing this tool produces feeds automatically into your existing R&D data stack.
Bottom line: Bet on Lumaris when you need a defensible literature synthesis fast before a board meeting or partnering discussion — not when you need a live feed of signals piped into your own pipeline.
Pricing Plans
- Free Tier
- Free sample report on request
Starter Brief
Single $49 brief
- One intelligence report
Full Report
$499 one-time
- Full structured report
Pro
$1,499 per quarter
- Quarterly engagement
View full pricing on lumaris.nanocorp.app →
Pricing may have changed since last verified. Check the official site for current plans.
Community Performance Report Card
No community ratings yet. Be the first to rate this tool!
Pros
Sign in to edit- Synthesizes findings across 35M+ indexed sources into a single cited report rather than returning a list of papers, so scientists get a defensible evidence base without spending weeks manually triangulating databases.
- Covers negative results, failed trials, and buried safety signals — not just published highlights — which means the team sees the full picture before committing resources to a target or indication.
- Scope is framed with help from an onboarding team, so the report addresses the actual strategic question rather than a generic topic dump that requires further filtering.
- No subscription required for initial reports, so a team can validate the quality of the output against a real question before committing to ongoing spend.
- Competitive pipeline mapping draws from both published literature and patent data, giving strategy teams a consolidated view rather than requiring parallel searches across separate databases.
Cons
Sign in to edit- There is no API and no integration path into existing data systems, so every insight produced lives in a report document — teams that need literature signals to flow automatically into internal pipelines or dashboards have to copy findings manually, which defeats the speed advantage at scale.
- The product is on-demand rather than continuous: you get a report when you ask for one, not a live alert when a competitor publishes a relevant preprint. Teams that need real-time monitoring of a therapeutic area will hit this ceiling quickly and move to dedicated competitive intelligence platforms built around continuous signal feeds.
- The scope of each report depends on how well the question is framed at the outset; the vendor acknowledges this by including an onboarding step, but if your team's question shifts mid-program — as it reliably does in drug discovery — you are ordering a new report rather than updating a living system.
- There is no self-hosted option, which means proprietary internal data — unpublished trial results, internal target hypotheses — cannot be incorporated into the synthesis. Teams whose key differentiator lives in non-public data get a report reflecting only what competitors can also find in the literature.
About
- API Available
- No
- Self-Hosted
- No
- Last Updated
- 2026-08-16T08:01:13.452Z
Best For
Who it's for
- Pharma R&D teams in oncology
- CNS and metabolic disease programs
- Competitive intelligence analysts
- Target validation scientists
What it does well
- Drug target identification
- Competitive landscape mapping
- Safety signal detection
- Post-trial literature synthesis
- Pipeline whitespace analysis
Add notes, reviews, and benchmarks so the next visitor gets a clearer picture.
Compare Lumaris
Spotted incorrect or missing data? Join our community of contributors.
Sign Up to ContributeFrequently Asked Questions
- Is Lumaris free?
- Lumaris has a permanent free tier alongside paid upgrades. You can keep using a baseline version indefinitely without paying.
- Is Lumaris open source?
- No — Lumaris is a closed-source tool. Source code is not publicly available.
Curated lists that include this category
The hidden cost of manual literature reviews
A senior scientist spending three months on a systematic literature review is three months not running experiments — and most teams accept that cost because they don’t have an alternative that doesn’t just return a pile of PDFs.
How it works
Lumaris generates structured intelligence reports from a defined therapeutic question. It pulls across PubMed, bioRxiv, clinical trial registries, patent literature, and preprint servers. The vendor states 35M+ papers indexed, updated daily. Users define the scope, an onboarding team helps frame the question, and a cited report with evidence strength ratings and identified gaps arrives within 48 hours. The workflow fits well for a pre-IND competitive scan or a target validation brief ahead of a portfolio review. It breaks down when teams need continuous monitoring with alerts rather than one-off reports.
Key strengths and limits
Pros include synthesizing findings across sources into a single cited report, covering negative results and failed trials, and scoping help from an onboarding team. Free sample report available on request. Cons are the lack of an API or integration path, plus the on-demand model rather than live alerts. Use cases cover drug target identification, competitive landscape mapping, safety signal detection, post-trial literature synthesis, and pipeline whitespace analysis.
Who it is for / who should skip it
Best for pharma R&D teams in oncology, CNS and metabolic disease programs, competitive intelligence analysts, and target validation scientists. Teams needing real-time monitoring of a therapeutic area or automatic flow into internal pipelines should skip it and look at dedicated competitive intelligence platforms instead.